INDIANAPOLIS, Nov. 14,
2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:
LLY) will attend the sixth annual Evercore ISI HealthCONx
Conference on Nov. 28,
2023. Daniel Skovronsky, M.D., Ph.D., executive vice
president, chief scientific and medical officer, and president of
Lilly Research Laboratories, will participate in a fireside chat at
3:50 p.m., Eastern time.
A live audio webcast will be available on the "Webcasts &
Presentations" section of Lilly's Investor website at
https://investor.lilly.com/webcasts-and-presentations. A replay of
the presentation will be available on this same website for
approximately 90 days.
About Lilly
Lilly unites caring with discovery
to create medicines that make life better for people around the
world. We've been pioneering life-changing discoveries for nearly
150 years, and today our medicines help more than 51 million
people across the globe. Harnessing the power of biotechnology,
chemistry and genetic medicine, our scientists are urgently
advancing new discoveries to solve some of the world's most
significant health challenges, redefining diabetes care, treating
obesity and curtailing its most devastating long-term effects,
advancing the fight against Alzheimer's disease, providing
solutions to some of the most debilitating immune system disorders,
and transforming the most difficult-to-treat cancers into
manageable diseases. With each step toward a healthier world, we're
motivated by one thing: making life better for millions more
people. That includes delivering innovative clinical trials that
reflect the diversity of our world and working to ensure our
medicines are accessible and affordable. To learn more,
visit Lilly.com and Lilly.com/news or follow us
on Facebook, Instagram and LinkedIn. F-LLY
Refer
to:
|
Jordan
Bishop; jordan.bishop@lilly.com; 317-473-5712
(Media)
|
|
Joe
Fletcher; jfletcher@lilly.com; 317-296-2884
(Investors)
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lilly-to-participate-in-evercore-isi-healthconx-conference-301986604.html
SOURCE Eli Lilly and Company